Rapid flurry of new drug pricing leaves no room for public debate | TheHill

Unfortunately, rather than celebrating these advances, we are left in shock at the cost. In August, Novartis announced the price of their CAR-therapy — a form of treatment primarily for blood cancers like leukemia and lymphoma — was $475,000 per patient based (although they may offer a refund for patients who do not benefit from the therapy).

Now, Kite Pharmaceutical has a CAR therapy lymphoma product for adults priced at almost $400,000. Speculation in the trade press on the price of Spark Therapeutics gene therapy for blindness suggest prices of up to $1,000,000.

This rapid flurry of unprecedented pricing benchmarks for new drugs has not given us time for public debate about the appropriateness of these pricing strategies, nor their impact on the health insurance premiums we all pay.

Read complete article here:

Rapid flurry of new drug pricing leaves no room for public debate | TheHill.